Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.51
Nov 17 • 10:31 AM ET Dollar change-0.09 Percentage change(-5.63%)
Today, 8:05 AMAdagene and City of Hope launched a Phase 1 trial of muzastotug (ADG126) plus ivonescimab in advanced microsatellite-stable colorectal cancer.
Index
-
Market Cap
101.38M
Enterprise Value
-3.89M
Income
-20.56M
Sales
9.32M
Book/sh
1.33
Cash/sh
1.91
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
128
IPO
Feb 09, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
10.88
P/B
1.13
P/C
0.79
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.42
Quick Ratio
5.02
Current Ratio
5.02
Debt/Eq
0.06
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-0.38
EPS next Y
-0.76
EPS next Q
-0.28
EPS this Y
-81.33%
EPS next Y
-39.71%
EPS next 5Y
-
EPS past 3/5Y
41.25% 21.03%
Sales past 3/5Y
-6.07% 61.40%
EPS Y/Y TTM
41.48%
Sales Y/Y TTM
8906.15%
EPS Q/Q
-
Sales Q/Q
-
Insider Own
18.49%
Insider Trans
0.38%
Inst Own
20.63%
Inst Trans
40.66%
ROA
-20.55%
ROE
-28.57%
ROIC
-19.17%
Gross Margin
94.22%
Oper. Margin
-240.31%
Profit Margin
-220.66%
SMA20
-31.95%
SMA50
-42.79%
SMA200
-55.64%
Trades
Shs Outstand
67.14M
Shs Float
54.73M
52W High
4.85 -68.87%
52W Low
1.42 6.53%
Volatility
19.56% 12.87%
ATR (14)
0.30
RSI (14)
27.12
Beta
0.74
Rel Volume
14.76
Avg Volume
278.07K
Volume
814,971
Perf Week
-26.34%
Perf Month
-34.06%
Perf Quarter
-63.35%
Perf Half Y
-55.59%
Perf YTD
-20.11%
Perf Year
-17.03%
Perf 3Y
10.22%
Perf 5Y
-83.87%
Perf 10Y
-
Prev Close
1.60
Price
1.51
Change %
-5.63%
Consensus
Strong Buy
Avg. Price Target
$8.40
Implied Upside
+456.3%
Analysts7incl. previous ratings
Rating Distribution6 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 10, 2026Initiated
CChardan Capital Markets
Buy$9+496.0%
Nov 24, 2025Initiated
GGuggenheim
Buy$9+496.0%
Aug 06, 2025Initiated
LLeerink Partners
Outperform$7+363.6%
Jan 31, 2025Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight
Jun 25, 2021Initiated
CChina Renaissance
Buy$40.57+2,586.8%
Mar 08, 2021Initiated
MS logoMMorgan Stanley
Overweight$34+2,151.7%
Mar 08, 2021Initiated
JEF logoJJefferies
Buy$33+2,085.4%
Mar 08, 2021Initiated
GS logoGGoldman
Buy$29+1,820.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tam Man KinChief Financial OfficerSep 23 '26Buy3.002,0006,00012,000Sep 25 06:23 PM
Luo PeterChief Executive OfficerSep 16 '26Buy3.1520,29063,98088,535Sep 17 06:11 AM
GU CHUNFANGOfficerAug 20 '26Proposed Sale3.9540,000158,000Aug 19 10:22 AM
DO CUONG VDirectorAug 14 '26Buy3.752,0007,5002,000Aug 18 06:11 PM
Luo PeterChief Executive OfficerAug 04 '26Buy3.6522,96683,74667,966Aug 06 06:15 PM
Luo PeterChief Executive OfficerAug 05 '26Buy3.652791,01868,245Aug 06 06:15 PM
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.
Co- FounderDr. Peter P. Luo Ph.D.
CFO & DirectorMr. Man Kin Tam M.B.A.
Executive Director & Head of Human ResourcesMs. Ling Zhou
Chief Manufacturing OfficerDr. Qinghai Zhao Ph.D.
Chief Strategy OfficerMr. Mickael Chane-Du